[Comparative clinical study of roxithromycin and josamycin for suppurative skin and soft tissue infections by a double-blind method].
The clinical efficacy and safety of Roxithromycin (RU 28965, RU), a new macrolide preparation, were compared with those of Josamycin (JM) in superficial suppurative skin infections. The study was designed as double-blind controlled trial with daily dosages of 300 mg in RU group and 1200 mg in JM group. A total of 209 cases (RU:105; JM:104) was analyzed and the final global improvement rating was 82.9% in the RU group and 80.8% in the JM group; there was no significant difference between the two groups. Slight adverse reactions were observed in 3.6% (4 cases) of the RU group and in 4.6% (5 cases) of the JM group. In conclusion, RU at daily doses of 300 mg is as effective as JM at daily doses of 1200 mg in superficial suppurative skin infections.
Nohara
N
N
Akagi
O
O
Kanzaki
H
H
Kanamoto
A
A
Ohara
A
A
Ohkawara
A
A
Fukaya
T
T
Kobayashi
H
H
Yasuda
H
H
Tagami
H
H
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013492:Suppuration
D007933:Leucomycins